Biocon's Siddharth Mittal Speaks On Selling Stake In Syngene & Viatris Biologics Biz Acquisition

Biocon's Siddharth Mittal Speaks On Selling Stake In Syngene & Viatris Biologics Biz Acquisition

Biocon Sells Another 10% Stake In Syngene: Siddharth Mittal Speaks On The Firm's Fund Raise Pipeline

Biocon Sells 5.4% Stake In Syngene To Fund Viatris Biologics Biz Acquisition | Halftime Report

Why Biocon Selling Stake in Syngene International ??💊💊

Big Pharma Firm Biocon's MD & CEO Siddharth Mittal On The Booming Obesity And Diabetes Drug Market

Siddharth Mittal, CEO & MD, Biocon, On Q4 Earnings, Pharma Market & Plans For Overseas Markets

Biocon Initiates Talks for Potential Stake Sale in Biosimilar Arm & Syngene | ET Now Exclusive

Biocon Q1 Results: Profit Drops 30% YoY To Rs 101 Cr | Siddharth Mittal | ET Now

Biocon To Invest $500 Mn For Capacities In Generics Biz In 5 Years Says MD & CEO, Siddharth Mittal

Biocon' Siddharth Mittal On Pipeline Of Biosimilar & Generic Drugs | BQ Prime

Biocon Q1 Earnings: PAT Soars 6X! Margin Miss, Growth Recovery Guidance & More | Siddharth Mittal

Siddharth Mittal in conversation with Alok Sinha & Sangram Surve

Guts, Glory & Story

Pharma firm Biocon elevates CFO Siddharth Mittal to CEO, joint MD

Syngene International Q4 : Net Profit Jumps 21% To YoY At ₹179 Crore | Jonathan Hunt Exclusive

Q1 Review | What Worked, What Didn't For Biocon

Q2 Review: After Weak Q2, Can Biocon Bounce Back In Q3? | BQPrime

ETNOW Exclusive - Why Biocon - Pfizer deal failed

Q1 Review: Biocon's Profit, Margins Fall, Misses Estimates | BQ Prime

Siddharth Mittal, CEO & MD, Biocon with Kumaar Bagrodia, Founder, NeuroLeap

CLO Chief Learning Officers Summit India

Biocon Biologics' Shreehas Tambe Speaks On The Firm's Deal With Japan's Yoshindo | CNBC-TV18